Companies Dominating the Bispecific Antibody Market
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Innovent Biologics, Ltd.
- Affimed GmbH
- Pieris Pharmaceuticals, Inc.
- Mereo BioPharma Group plc
- TG Therapeutics, Inc.
- MacroGenics, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- AbbVie, Inc.
- Roche
- Sanyou Biopharmaceuticals Co., Ltd.
- Orion Corporation
- Amgen Inc.
The presence of research-based key pharma developers is expanding the pipeline of the market. They are competitively innovating new therapeutics and identifying extended indications to solidify their leadership. For instance, in May 2024, Amgen attained FDA approval for its Imdelltra (tarlatamab-dlle) in treating extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. In the same timeframe, Regeneron Pharmaceuticals achieved positive endpoints phase 1/2 trial on its first-in-class costimulatory bispecific antibody, REGN7075 (EGFRxCD28), in combination with Libtayo (cemiplimab) for treating patients with advanced solid tumors. This cohort of pioneers includes:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of bispecific antibody is assessed at USD 605.9 million.
The global bispecific antibody market is projected to grow from USD 98.6 billion in 2024 to USD 1.44 billion by 2037, exhibiting a CAGR of over 7.3% during the forecast period, between 2025 and 2037.
North America industry is estimated to dominate majority revenue share of 35% by 2037, due to rising demand for targeted and personalized therapies in the region.
The major players in the market include F. Hoffmann-La Roche Ltd., Innovent Biologics, Ltd., Affimed GmbH, Pieris Pharmaceuticals, Inc., Mereo BioPharma Group plc, TG Therapeutics, Inc., MacroGenics, Inc., Pfizer Inc., GlaxoSmithKline plc, AbbVie, Inc.
